Search
Qiagen NV
QGENAdd to Watchlist
40.100USD
+0.980+2.50%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.27BMarket Cap
21.46P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.50%
5 Days
+1.75%
1 Month
+6.76%
6 Months
-11.41%
Year to Date
-10.98%
1 Year
-17.05%
Key Figures
40.000Open
40.180High
1.63MVolume
21.46P/E TTM
15.53P/E Dynamic
0.250Dividend TTM
0.79%Turnover Ratio
39.130Prev. Close
39.750Low
40.25MTurnover
98.94P/E Static
2.48P/B
0.62%Div Yield TTM
7.10%ROA
57.81552wk High
1.02Volume Ratio
83.59MNet Profit
206.25MShares
1.8687EPS TTM
0.66Beta
11.93%ROE
32.53052wk Low
1.10%Amplitude
62.41%Gross Margin
8.27BMarket Cap
2.28Reward/Risk
1.83%Risk Rate
TradingKey Stock Score of Qiagen NV
Currency: USD Updated: 2026-07-02Key Insights
Qiagen NV's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.45.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Qiagen NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
No data
Qiagen NV Highlights
StrengthsRisks
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.09B.
Undervalued
The company’s latest PE is 21.46, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.40M shares, decreasing 15.71% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 93.00K shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
44.448
Target Price
+13.59%
Upside Space
Qiagen NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Qiagen NV Info
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Ticker SymbolQGEN
CompanyQiagen NV
CEOBernard (Thierry)
Websitehttps://www.qiagen.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Qiagen NV (QGEN)?
The current price of Qiagen NV (QGEN) is 40.10.
What is the symbol of Qiagen NV?
The ticker symbol of Qiagen NV is QGEN.
What is the 52-week high of Qiagen NV?
The 52-week high of Qiagen NV is 57.81.
What is the 52-week low of Qiagen NV?
The 52-week low of Qiagen NV is 32.53.
What is the market capitalization of Qiagen NV?
The market capitalization of Qiagen NV is 8.27B.
Is Qiagen NV (QGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Qiagen NV (QGEN) has an overall rating of Buy, with a price target of 44.45.
What is the Earnings Per Share (EPS TTM) of Qiagen NV (QGEN)?
The Earnings Per Share (EPS TTM) of Qiagen NV (QGEN) is 1.96.